Insilico Medicine and Human Longevity Partner on AI Foundation Model for Longevity Research

Insilico Medicine and Human Longevity announced a collaboration to co-develop what the companies describe as an AI foundation model focused on longevity science and aging research. The initiative will combine biological, clinical and longevity-related datasets to create AI models capable of supporting research into aging mechanisms, disease prevention, and healthspan extension. The goal is to accelerate scientific discovery and improve understanding of age-related conditions through large-scale computational analysis.

The collaboration between Insilico and HLFM aims to jointly develop a super-intelligence AI foundation model to decode the biological mechanisms of aging and enable predictive healthcare. The companies believe that these advancements will play a pivotal role in the future of medicine by shifting the global healthcare paradigm from reactive disease treatment toward proactive and preventive longevity science.

Insilico Medicine, known for applying AI to drug discovery, said the collaboration expands its work in biomedical modeling and predictive research. Human Longevity will contribute genomic and health-related data to support development of the foundation model.

Posted by MedCloudInsider Editors on 05/26/2026